What is the 13F Pro Quality Score for ENSC?

13F Pro ranks Ensysce Biosciences, Inc. (ENSC) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ENSC's current score at https://13fpro.ai/company/ENSC (free sign-up required for the full ranking).

Which hedge funds own the most ENSC stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of ENSC include JANE STREET GROUP,, ADAGE CAPITAL PARTNERS GP, L.L.C., Virtu Financial. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/ENSC as soon as new 13F filings post.

Where does 13F Pro source ENSC data?

All Ensysce Biosciences, Inc. fundamentals and ownership data come directly from SEC EDGAR. Ensysce Biosciences, Inc. files with the SEC under CIK 1716947. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ENSC in?

Ensysce Biosciences, Inc. (ENSC) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ENSC research updated on 13F Pro?

ENSC's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Ensysce Biosciences, Inc.(ENSC)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1716947 ENSC stock profile & AI dashboard →

13F Pro Quality Score

29.2/100

Rank #2,536 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why ENSC Scores 29/100

exact factor attribution · 2026-09-11

ENSC's composite is driven by revenue growth, held back by scale and profitability. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+9.0 pts

95th pct

Shareholder dilution

-0.8 pts

34th pct

Earnings quality

-1.4 pts

36th pct

Institutional flow

-1.5 pts

21th pct

Earnings growth

-2.2 pts

5th pct

Capital efficiency

-4.9 pts

1th pct

Free cash flow

-6.1 pts

9th pct

Profitability

-6.2 pts

9th pct

Scale

-6.8 pts

5th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

ENSC Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Ensysce Biosciences, Inc. (ENSC), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ENSC at 29.2/100 on a 32-signal composite quality model, placing it at rank #2,536 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Ensysce Biosciences, Inc. reports quarterly revenue of $1.2M, net income of $-2.6M. Top institutional holders of ENSC by reported 13-F value include JANE STREET GROUP, ADAGE CAPITAL PARTNERS GP, L.L.C., Virtu Financial, based on the most recent SEC filings. ENSC trades on the Nasdaq exchange and files with the SEC under CIK 1716947. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ENSC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Ensysce Biosciences, Inc. directly from SEC EDGAR. Ensysce Biosciences, Inc.'s 13F Pro composite quality score has ranged between 14 and 29 since 2026, currently 29.2 — a stable long-term trajectory across 8 quarterly and live scoring snapshots.

✦

Fun facts about Ensysce Biosciences, Inc.

Quirks, history, and lore behind ENSC — the kind of stuff that makes a stock memorable.

1
The Basics
A clinical-stage biopharmaceutical company · listed on Nasdaq · headquartered in Southern California · focused on controlled-substance drug abuse.
2
The Numbers
A micro-cap with minimal revenue — as with most clinical-stage biotechs, the balance sheet is more cash burn than cash flow while pipeline programs advance.
3
The History
Born out of research into opioid misuse prevention, the company went public via a SPAC merger in the early 2020s, riding a wave of investor interest in addiction medicine.
4
The Secret
Its core trick is chemistry: proprietary abuse-deterrent technology that makes opioids and stimulants inert or unpleasant if someone tries to snort, inject, or overload them.
5
The Lore
Its lead platform targets the fentanyl crisis head-on — designing prescription opioids that self-destruct when abused, which is either brilliant or a very hard sell to regulators.
6
The Giveaway
The name itself is a mashup of "enzyme" and "science" — a biotech devoted entirely to making opioids and stimulants abuse-proof through enzymatic chemistry.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$1.2M

Net Income

Q2 2026

$-2.6M

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

-2.8% YoY

$5.1MFY 2025

FY22 $2.5MFY23 $2.2MFY24 $5.2MFY25 $5.1M

Net Income

—FY 2025

FY22 —FY23 —FY24 —FY25 —

Operating Income

-52.2% YoY

$-10.2MFY 2025

FY22 $-24.2MFY23 $-10.7MFY24 $-6.7MFY25 $-10.2M

EPS (Diluted)

+65.2% YoY

$-1.99FY 2025

FY22 $-1.99FY23 $-1.01FY24 $-5.72FY25 $-1.99

Total Assets

+33.1% YoY

$7.5MFY 2025

FY22 $5.9MFY23 $2.7MFY24 $5.6MFY25 $7.5M

Op. Cash Flow

-4.0% YoY

$-7.8MFY 2025

FY22 $-17.9MFY23 $-10.8MFY24 $-7.5MFY25 $-7.8M

Free Cash Flow

$-7.9MFY 2025

FY22 —FY23 —FY24 —FY25 $-7.9M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$5.1M -2.8%	$5.2M +133.6%	$2.2M -11.6%	$2.5M -28.5%	$3.5M -10.2%	$3.9M
Net Income	—	—	—	—	—	$4.3M
Operating Income	$-10.2M -52.2%	$-6.7M +37.2%	$-10.7M +55.8%	$-24.2M -21.9%	$-19.9M -1351.6%	$-1.4M
EPS (Diluted)	$-1.99 +65.2%	$-5.72 -469.3%	$-1.01 +49.5%	$-1.99 -484.9%	$-0.34	$0.00
Total Assets	$7.5M +33.1%	$5.6M +106.7%	$2.7M -54.0%	$5.9M -64.2%	$16.4M +4566.6%	$351.8K
Operating Cash Flow	$-7.8M -4.0%	$-7.5M +30.4%	$-10.8M +39.7%	$-17.9M -117.0%	$-8.2M -853.5%	$-864.4K
Free Cash Flow	$-7.9M	—	—	—	—	—

Get alerted when ENSC's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Ensysce Biosciences, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ENSC

JANE STREET GROUP, LLC
$60.6K208,833 sh
ADAGE CAPITAL PARTNERS GP, L.L.C.
$43.4K149,711 sh
Virtu Financial LLC
$28.0K95,391 sh
PERCEPTIVE ADVISORS LLC
$25.1K86,666 sh
CITADEL ADVISORS LLC
$25.0K86,193 sh
XTX Topco Ltd
$22.3K77,005 sh
GEODE CAPITAL MANAGEMENT, LLC
$18.0K62,188 sh
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$9.9K34,280 sh
TRU INDEPENDENCE ASSET MANAGEMENT 2, LLC
$3.8K13,000 sh
TWO SIGMA SECURITIES, LLC
$3.8K12,953 sh

Fund	Value	Shares
JANE STREET GROUP, LLC	$60.6K	208,833
ADAGE CAPITAL PARTNERS GP, L.L.C.	$43.4K	149,711
Virtu Financial LLC	$28.0K	95,391
PERCEPTIVE ADVISORS LLC	$25.1K	86,666
CITADEL ADVISORS LLC	$25.0K	86,193
XTX Topco Ltd	$22.3K	77,005
GEODE CAPITAL MANAGEMENT, LLC	$18.0K	62,188
SUSQUEHANNA INTERNATIONAL GROUP, LLP	$9.9K	34,280
TRU INDEPENDENCE ASSET MANAGEMENT 2, LLC	$3.8K	13,000
TWO SIGMA SECURITIES, LLC	$3.8K	12,953

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ENSC on your watchlist

Track score changes the day Ensysce Biosciences, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ENSC a good stock to buy?

13F Pro's AI-powered analysis of Ensysce Biosciences, Inc. (ENSC) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ENSC are available on the ENSC stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ENSC is classified as a small company.

Which hedge funds own ENSC?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ENSC. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Ensysce Biosciences, Inc.'s investment landscape.